MVC-COV1901

A COVID-19 candidate protein subunit vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

2
Supporting references
0
Contradictory references
3
Clinical trials

General information

MVC-COV1901 is a COVID-19 candidate protein subunit vaccine being developed by Medigen Vaccine Biologics Corporation/NIAID/Dynavax. It is based on a prefusion SARS-CoV-2 spike immunogen with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide serving as adjuvants (Kuo et al., 2020). Currently, this COVID-19 candidate vaccine is being evaluated in Phase I clinical trial. 


Synonyms

S-2P subunit vaccine


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
mixed substance animal model protein factor
HEK293-hACE2 cells; Vero E6 cells; female BALB/c and C57BL/6 mice; Wuhan-Hu-1 strain SARS-CoV-2 spike protein pseudovirus; live SARS-CoV-2 (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759)

Used with CpG 1018 (a Th1-biasing synthetic toll-like receptor 9 agonist) and aluminum hydroxide as adjuvants, the candidate vaccine induced high titer of neutralizing antibodies against pseudotyped virus or live SARS-CoV-2 in sera of immunized mice. No serious adverse reactions were noted.

Nov/29/2020 Nov/29/2020
Draft landscape of COVID-19 candidate vaccines healthy adults Jul/28/2020 Aug/06/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04822025 A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults Recruiting Phase 2 May/20/2021 Jan/01/2022
NCT04695652 A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult Active, not recruiting Phase 2 Dec/30/2020 Jun/01/2022
NCT04487210 A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19 Active, not recruiting Phase 1 Oct/07/2020 Nov/30/2021